Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on hepatocyte-targeting efficiency in vitro and in vivo

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3033-3050

  Xiao, Yan ^a   Zhang, Huafang ^a   Zhang, Zhaoguo ^a   Yan, Mina ^a   Lei, Ming ^a   Zeng, Ke ^a   Zhao, Chunshun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

ASGP R; Doxorubicin; Galactose; Liposomes; Pharmacokinetics; Targeted drug delivery

Indexed keywords

AMMONIUM SULFATE; ASIALOGLYCOPROTEIN RECEPTOR; DOXORUBICIN; DRUG CARRIER; GALACTOSE; LIPOSOME; TETRAVALENT GALACTOSYLATED DIETHYLENETRIAMINEPENTAACETIC ACID DISTEAROYL PHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CHEMICAL STRUCTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SINGLE DRUG DOSE; SYNTHESIS;

ASGP-R; DOXORUBICIN; GALACTOSE; LIPOSOMES; PHARMACOKINETICS; TARGETED DRUG DELIVERY;

ANIMALS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GALACTOSE; HEP G2 CELLS; HUMANS; LIPOSOMES; LIVER; MALE; MICE; PENTETIC ACID; PHOSPHATIDYLETHANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84881591605     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S47495     Document Type: Article

References (50)

1. Li L, Wang H, Ong ZY, et al. Polymer-and lipid-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today. 2010;5(4): 296-312.
2. Wang S, Xu H, Xu J, et al. Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-Lipid. AAPS PharmSciTech. 2010;11(2):870-877.
3. Smith JS, Xu Z, Byrnes AP. A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells. J Virol Methods. 2008;147(1):54-60.
4. Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev. 1995;75(3):591-609.
5. Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. J Control Release. 2012;161(2):188-197.
6. Spiess M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry. 1990;29(43):10009-10018.
7. Geffen I, Spiess M. Asialoglycoprotein receptor. Int Rev Cytol B. 1992;137:181-219.
8. Baenziger J, MaynardY. Human hepatic lectin. Physiochemical properties and specificity. J Biol Chem. 1980;255(10):4607-4613.
9. Baenziger J, Fiete D. Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. Cell. 1980;22(2 Pt 2):611-620.
10. Lee YC, Townsend RR, Hardy MR, et al. Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. J Biol Chem. 1983;258(1):199-202.
11. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials. 2007;28(7): 1434-1442.
12. Mandal A, Das S, Basu M, Chakrabarti R, Das N. Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis. J Pharmacol Exp Ther. 2007;320(3):994-1001.
13. Managit C, Kawakami S, Yamashita F, Hashida M. Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. J Pharm Sci. 2005;94(10):2266-2275.
14. Murao A, Nishikawa M, Managit C, et al. Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition. Pharm Res. 2002;19(12):1808-1814.
15. Mammen M, Choi SK, Whitesides GM. Polyvalente Wechselwirkungen in biologischen Systemen: Auswirkungen auf das Design und die Verwendung multivalenter Liganden und Inhibitoren. Polyvalent interactions in biological systems: implications for the design and use of multivalent ligands and inhibitors Angewandte Chemie. 1999;110(20):2908-2953. German.
16. Kawakami S, Munakata C, Fumoto S, Yamashita F, Hashida M. Targeted delivery of prostaglandin E1 to hepatocytes using galactosylated liposomes. J Drug Target. 2000;8(3):137-142.
17. Grant CWM, Karlik S, Florio E. A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA. Magn Reson Med. 1989;11(2): 236-243.
18. Ishiwata H, Vertut-Doï A, Hirose T, Miyajima K. Physical-chemistry characteristics and biodistribution of poly(ethylene glycol)-coated liposomes using poly(oxyethylene) cholesteryl ether. Chem Pharm Bull. (Tokyo). 1995;43(6):1005-1011.
19. Yeagle PL. Cholesterol and the cell membrane. Biochimica et Biophysica Acta. 1985;822(3-4):267-287.
20. Gleason MM, Medow MS, Tulenko TN. Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res. 1991;69(1): 216-227.
21. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J. 1980;186(2):591-598.
22. Khorev O, Stokmaier D, Schwardt O, Cutting B, Ernst B. Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Biorg Med Chem. 2008;16(9):5216-5231.
23. Feng L, Zhang L, Yan Z, Gu B, Wang C, LuW. Experimental study on liposomal drug delivery system for lymphatic targeting. Acta Biophysica Sinica. 2010;26:735-749.
24. Zhu S, Li Y, Yu B. Synthesis of betavulgaroside III, a representative triterpene seco-glycoside. J Org Chem. 2008;73(13):4978-4985.
25. Zhao H, Li X, Liu H, Li Y, Wu C. Synthesis and characterization of ferrocenylmethylaminobenzoic acids and their glucosyl esters. Synth React Inorg Met Org Chem. 2000;30(3):473-483.
26. Park IY, Kim TH, Kim YK, Choi YJ, Nah JW, Cho CS. Galactosylated chitosan/carbonate apatite nanohybridization for cell specificity and high transfection efficiency as a DNA carrier. Key Eng Mater. 2007;342: 437-440.
27. Park I-K, Jiang H-L, Cook S-E, et al. Galactosylated chitosan (GC)-graftpoly (vinyl pyrrolidone)(PVP) as hepatocyte-targeting DNA carrier: in vitro transfection. Arch Pharm Res. 2004;27(12): 1284-1289.
28. Zhang X-Q, Wang X-L, Zhang P-C, et al. Galactosylated ternary DNA/ polyphosphoramidate nanoparticles mediate high gene transfection efficiency in hepatocytes. J Control Release. 2005;102(3):749.
29. Jere D, Jiang H, Arote R, et al. Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin Drug Deliv. 2009;6(8): 827-834.
30. Park I, Kim T, Kim S, et al. Visualization of transfection of hepatocytes by galactosylated chitosan-graft-poly (ethylene glycol)/DNA complexes by confocal laser scanning microscopy. Int J Pharm. 2003;257(1): 103-110.
31. Jiang H-L, Kwon J-T, Kim E-M, et al. Galactosylated poly (ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocytetargeting. J Control Release. 2008;131(2):150-157.
32. Díez S, Miguéliz I, De Ilarduya CT. Targeted cationic poly (D, L-lacticco-glycolic acid) nanoparticles for gene delivery to cultured cells. Cell Mol Biol Lett. 2009;14(2):347-362.
33. Longmuir KJ, Haynes SM, Baratta JL, Kasabwalla N, Robertson RT. Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate. Int J Pharm. 2009;382(1):222-233.
34. Baratta JL, Ngo A, Lopez B, Kasabwalla N, Longmuir KJ, Robertson RT. Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis. Histochem Cell Biol. 2009;131(6):713-726.
35. Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001;90(6):667-680.
36. Gabbay E, Grier D, Fingerle R, et al. Interaction specificity of the anthracyclines with deoxyribonucleic acid. Biochemistry. 1976;15(10): 2062.
37. Coley H, Amos W, Twentyman P, Workman P. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer. 1993;67(6):1316.
38. Marquardt D, Center MS. Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res. 1992;52(11): 3157-3163.
39. Düzgüneş N, Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Del Rev. 1999;40(1):3-18.
40. Liu X, Chua CC, Gao J, et al. Pifithrin-α protects against doxorubicininduced apoptosis and acute cardiotoxicity in mice. Science Signaling. 2004;286(3):H933.
41. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992;52(4):891-896.
42. Gabizon A, Isacson R, Libson E, et al. Clinical studies of liposomeencapsulated doxorubicin. Acta Oncol. 1994;33(7):779-786.
43. Gabizon A, Meshorer A, Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst. 1986;77(2): 459-469.
44. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002;4(3):95.
45. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am. 1994;8(2):431.
46. Olson F, Mayhew E, Maslow D, Rustum Y, Szoka F. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol. 1982;18(2):167-176.
47. Chen ZG. Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med. 2010;16(12):594-602.
48. Wang R, Billone PS, Mullett WM. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J Nanomater. 2013. doi:10.1155/2013/629681
49. Chandaroy P, Sen A, Alexandridis P, Hui SW. Utilizing temperaturesensitive association of Pluronic F-127 with lipid bilayers to control liposome-cell adhesion. Biochimica et Biophysica Acta. 2002;1559(1): 32-42.
50. Xiang Y, Liang L, Wang X, Wang J, Zhang X, Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release. 2011;152(3): 402-410.